COST Action CA20113 Encourage the participation of new Inclusiveness Target Countries (ITCs) and Near Neighbour Countries (NNCs) in International Meetings and Conferences.
COST Action CA21113, Genome editing for the treatment of human disease: Gene-Humdi, is opening the 2024 call for Inclusive Target Countries and Near Neighbour Countries. We provide funding opportunities to ITC and NCC members attending to Conferences and Meetings aligned with mission of the GeneHumdi Network. You can prepare by learning more about our mission at www.genehumdi.eu or looking for a suitable mentor among our amazing members listed HERE.
2024.08.06 UPDATE
We are funding ESGCT presenting students!!
⚠Be aware of 2024 policies ⚠
Applications will only be considereduntil October 1st, or until the ITC budget for the Grant Period 2 (GP2).
The GP2 finalizes at the end of October.
Eligible conferences must fall within the current GP2. Consider that COST do not allow processing payments for GP2 ITCS/NCCs once the grant period is over. Beware of conferences that are too close to the deadline.
Close to the end of the GP2, grantees attending to conferences or visiting GeneHumdi laboratories, will be invited to share their experiences and achievements in a virtual conference/meeting.
COST Action 20113 Encourage the participation of new Inclusiveness Target Countries (ITCs) and Near Neighbour Countries (NNCs) in Action activities.
COST Action CA21113, Genome editing for the treatment of human disease: Gene-Humdi, is opening the 2024 call for Inclusive Target Countries and Near Neighbour Countries. We provide funding opportunities to ITC and NCC members attending to Conferences and Meetings aligned with mission of the GeneHumdi Network. You can prepare by learning more about our mission at www.genehumdi.eu or looking for a suitable mentor among our amazing members listed HERE.
2024.03.05 UPDATE
As now the first call for ICT/NCC applicants is Open!!
⚠Be aware of 2024 policies ⚠
Applications will only be considereduntil October 1st, or until the ITC budget for the Grant Period 2 (GP2).
The GP2 finalizes at the end of October.
Eligible conferences must fall within the current GP2. Consider that COST do not allow processing payments for GP2 ITCS/NCCs once the grant period is over. Beware of conferences that are too close to the deadline.
Close to the end of the GP2, grantees attending to conferences or visiting GeneHumdi laboratories, will be invited to share their experiences and achievements in a virtual conference/meeting.
Moroccan Society of Genomics and Human Genetics (SM2GH) and Spanish Society of Gene and Cell Therapy (SETGyC) Forge Strategic Collaboration
The Moroccan Society of Genomics and Human Genetics (SM2GH) and the Spanish Society of Gene and Cell Therapy (SETGyC) are thrilled to announce a groundbreaking collaborative agreement, signed on Friday, October 20th, 2023, to advance scientific and educational cooperation between the two esteemed organizations.
This historic collaboration aims to foster partnerships between the SM2GH and the SETGyC, focusing on the pivotal domains of human genetics, immunogenetics, genome editing, and the development of gene and cell therapies. At the core of this alliance is a shared commitment to nurturing the growth and development of young researchers, regardless of their Moroccan or Spanish origins.
Key objectives of this collaborative agreement include:
Student and Young Researcher Training: Both societies are dedicated to equipping the next generation of scientists with the knowledge and skills needed in the fields of genome editing, gene therapy, and cell therapy.
Training of Trainers: The collaboration will facilitate the training of trainers in the specialized areas of genome editing and gene and cell therapy, ensuring a sustainable knowledge transfer process.
Joint Educational Initiatives: SM2GH and SETGyC will co-organize a series of courses, workshops, and conferences that cater to the scientific interests of both societies. These events will serve as hubs for knowledge exchange and collaboration, bringing together experts from both Morocco and Spain.
The implementation of this agreement will also be facilitated through the Cost Action CA21113, “Gene Editing for the Treatment of Human Diseases” (GenEHumDi). By leveraging this initiative, Professor Khalid Sadki, the Founder and President of SM2GH, will embark on a Short Term Scientific Mission (STMS) to Donostia, Spain, further strengthening the bonds of cooperation between the two societies. The meeting in Donostia witnessed the historic agreement being co-signed by Professor Ander Izeta, President of SETGyC, and Professor Khalid Sadki, the visionary leader behind SM2GH.
The signing of this collaborative agreement represents a significant milestone in the pursuit of scientific excellence, cross-cultural understanding, and the advancement of human genetics, genome editing, and gene and cell therapy. Both SM2GH and SETGyC are committed to nurturing the talent of young scientists and researchers in Morocco and Spain, ushering in a new era of scientific progress and innovation.
The Moroccan Society of Genomics and Human Genetics (SM2GH) is a leading scientific organization dedicated to advancing research and education in the fields of genomics and human genetics in Morocco. Founded by Professor Khalid Sadki, SM2GH is committed to promoting scientific excellence, fostering collaboration, and facilitating knowledge exchange among professionals and students in Morocco and beyond. More information in its website: https://www.sm2gh.ma/
About SETGyC
The Spanish Society of Gene and Cell Therapy (SETGyC) is a distinguished institution at the forefront of research and development in gene and cell therapies in Spain. Led by President Professor Ander Izeta, SETGyC is focused on driving scientific innovation, fostering educational initiatives, and facilitating partnerships within the field of gene and cell therapy. Find more in : https://www.setgyc.es/
About GenEHumDi
The GENome Editing for the treatment HUMan DIseases (GenEHumdi|COST Action 21113) is an EU funded initiative to fuel promotion of laboratory proven Genome Editing technologies towards clinical implementation. Such therapeutic strategies requires coordination and of basic, applied, industrial, and pharmaceutical scientist in addition to industry and regulatory agencies. This initiative is currently chaired by prof, Karim Benabdel and Alessia Cavazza.
[Granada, October 2023] – COST Action CA21113 is thrilled to announce a new open call for Virtual Mobility (VM) grants, offering an outstanding opportunity for researchers and innovators to engage in virtual collaborations that can accelerate your career and broaden your network.
5 Grants Available!
We’re allocating a total of 5 Virtual Mobility grants, opening doors for enthusiastic individuals ready to embark on a journey of knowledge exchange, skill enhancement, and networking within the COST Action community.
What is Virtual Mobility (VM)?
Virtual Mobility is a dynamic collaboration in a virtual setting among researchers or innovators within the COST Action network. It allows participants to exchange knowledge, learn new techniques, and contribute to the advancement of European knowledge creation and innovation potential.
Why should you apply for a VM grant?
For COST Action: VM grants are a flexible tool to implement virtual activities, achieve MoU objectives, and increase our European impact and reach.
For VM Grantees: By participating in VM activities, you’ll develop essential capacities in virtual collaboration and networking within a pan-European framework, enhancing your career and skills.
Opportunities Await
COST Action CA21113 is looking for researchers to undertake the following tasks within the Virtual Mobility program:
Virtual Mentoring Scheme: Focus on activities and exchanges that build capacity and new skills, particularly for Young Researchers and Innovators.
Harmonization and Standardization: Support the standardization of methods and procedures within our network through coordination and preparation.
Research Coordination Activities: Assist in activities that do not require in-person presence, such as computational or modeling tasks and data analysis.
Application Details
To apply for a VM grant, you’ll need to prepare:
Title: A concise title for your proposed activity.
Start and End Date: Ensure it falls within the active Grant Period.
Budget Requested: Specify the budget you require.
Additionally, you must upload:
Application Form: Utilize the provided template on e-COST, describing your main objective, work plan, participation strategy, expected outcomes, and how your activity contributes to the Action MoU objectives.
Other Required Documents: Any additional documents requested by the Action (e.g., recommendation letters, etc.).
Important Dates
Application Deadline: Submit your proposals by 15/10/2023.
Reporting and Payment Claim: Submit required reports and documentation via e-COST by 5th November 2023.
Funding Scheme
Name: Virtual Mobility Grant
Scope: Providing a contribution for the overall effort.
Maximum Amount (EUR): Up to EUR 1,500.00 per grant.
Decision of the Amount: Decided by the Action MC or Core Group based on evaluator recommendations, reflecting the task’s duration, scope, and complexity.
Don’t miss this incredible opportunity to elevate your research and innovation skills. Contact our Grant Holder Manager, Maria Bazuelo, at 📩 mariaj.bazuelo@juntadeandalucia.es for details and application guidance.
Gene Editing for treatment of Humans diseases ( GenEHumDi) COST Action CA21113 fosters collaboration and innovation among European researchers and innovators. Our Virtual Mobility program empowers individuals with tools to excel in their fields and contribute to the European research community.
[Granada, July 15th 2023] – The GenE-Humdi action (Genome Editing to Treat Humans Diseases) is announcing its second call for applications for to promote young researchers mobility and participation in European forums. The initiative aims to encourage researchers from EU member countries and near neighbor countries, with emphasis in Inclusiveness Target Countries, to participate in conferences and short-term scientific visits, promoting collaboration and knowledge exchange.
Inclusive Target Countries Conference Grants:
Funding available for researchers from: Albania, Armenia, Bosnia and Herzegovina, Bulgaria, Cyprus, Czech Republic, Estonia, Croatia, Georgia, Greece, Hungary, Lithuania, Latvia, Malta, Moldova, Montenegro, Poland, Portugal, Romania, Slovenia, Slovakia, Republic of North Macedonia, Republic of Serbia, Turkey and Ukraine.
Check updated listo f countries >here< specific countries to attend conferences aligned with the project’s objectives.
Maximum grant amount: €2000.
Applications evaluated based on conference relevance and the proposed contribution to project goals.
Applicants must be affiliated with institutions in the eligible countries and meet certain criteria.
No fixed deadline, but grants awarded on a first-come, first-served basis until funds are depleted.
Short-Term Scientific Missions (STSMs):
Researchers have the opportunity to visit institutions in other countries to strengthen networks and gain new knowledge. STSMs contribute to the project’s scientific objectives and allow researchers to learn new techniques. They are invaluable tool in young researcher development.
Maximum grant amount: €4000.
Eligible researchers from COST member countries and neighboring regions can apply, with preference given to young researchers.
No fixed deadline, but grants awarded on a first-come, first-served basis until funds are depleted.
For more information and to apply, visit the GenE-Humdi official webpage and refer to the Grant Awarding User Guide on the e-COST system or contact ITC Coordinators or Grant Coordinators (GeneHumdi Leadership postition with contact links).
GenE-Humdi is a collaborative project focused on advancing genome editing research to treat human diseases. The project promotes inclusive participation, research training, and international collaboration.
Why Engage in Short-Term Scientific Missions (STSMs)?
The GeneHumdi board is pleased to introduce Short-Term Scientific Missions (STSMs) funded by the prestigious COST Action program. These missions are designed to foster collaboration, strengthen networks, and facilitate knowledge exchange among researchers. By participating in STSMs, you gain access to research institutions or laboratories in other COST countries, enabling you to learn new techniques, utilize advanced equipment and methods, and contribute to the scientific objectives of the Action. Embrace this unique opportunity to expand your horizons, establish fruitful collaborations, and make significant strides in your research endeavors.
Harness the Power of Top Gene Editing Research groups in Europe
Participants in the COST Action’s Short-Term Scientific Missions (STSMs) have the freedom to focus their work on research topics highlighted by each GeneHumdi Working Group (WGs). Additionally, you have the liberty to introduce innovative ideas that align with the objectives of our Action. Explore the detailed content and goals of each WG in the Action’s Memorandum of Understanding (MoU). By aligning your STSM proposal with the scope of the dedicated WGs, you can maximize the impact of your research while contributing meaningfully to the GeneHumdi mission and to your field.
Guidelines for Applicants:
Financial Support: Successful applicants will receive travel grants for four Short-Term Scientific Missions (STSMs) offered by GeneHumdi. It is the responsibility of the grantees to arrange their travel, accommodation, and other logistics. During this period, STSM grants are awarded up to a maximum of €4,000. We encourage applicants to review the Annotated Rules for COST Actions to understand the financial framework.
Duration: STSMs must be completed within the 1st Grant Period of the Action, which concludes in October 2023. While there is no maximum duration for visits, the minimum visit should be at least 5 days,including travel time.
Application Deadline: Submit your applications by June 18th, 2023. Notification of decisions will be made by June 30th, 2023.
Eligibility: STSM travel grants are open to researchers and innovators associated with a legal entity in a COST Full/Cooperative Member, Near Neighbour Country, or European RTD. While all eligible candidates are encouraged to apply, young researchers and innovators under the age of 40 are particularly encouraged to participate.
Application Instructions: To apply for an STSM, utilize the e-COST management tool. Please ensure that you possess an e-COST profile, as it is mandatory for all applicants.
Submission Requirements: Use the e-COST management tool to submit your request for an STSM. Alongside the necessary information provided on the website, applicants are required to upload specific documents in a single PDF file, including:
A brief CV highlighting your recent publications.
The STSM proposal, outlining your research objectives and methodology.
Each STSM must be aligned with one of the following topics:
Topic 1: Mapping the existing endonuclease-Independ platforms (EIP) and their potential output in different applications, efficacy, specificity of the available endonucleases independent GE tools.
Topic 2: Mapping the existing endonuclease platforms (EIP) and their potential output in different applications, efficacy, specificity of the available endonucleases independent GE tools
Topic 3: Delivery methods used for GE of the different cell types that are used for clinical applications. non-viral systems, based on ribonucleoparticles (RNP) or plasmids, are the ex vivo systems of choice to deliver the GE complex into the target cells.
Topic 4: Delivery methods used for in vivo GE in different animal models and in clinical settings. Including comparison of efficacy and specificity data for different GE tools delivered by different methods in each tissue/organ of interest.
Topic 5: The establishment of a standardized pipeline for the unbiased identification and quantification of CRISPR off-target sites for therapeutic applications.
Topic 6: Assessment of recombination events in gene editing approaches
Topic 7: Comparison of the different constrains in the HDR-mediated gene editing in the most primitive HSPCs, and how the HDR may be enhanced.
Topic 8: The evaluation of different GE strategies to target Hematopoietic stem cells in Fanconi anaemia cells in vitro, the sickle cell disease and beta-thalassemia, collagen VI deficiency and Emery Derfuss muscular dystrophy.
Topic 9: Market research study and competitive analysis on gene editing based medicines including the following tasks: (i) Market opportunity. Target niche; (ii) Definition of targeted market, sales by category (product, territory, class and market share (sales peak, defining at least three different scenarios), positioning, market drivers and barriers.
Topic 10: The analyse of regulatory requirements for the commercialization of gene editing based medicines.
The Genome Editing to Treat Humans Diseases (GeneHumdi | COST Action CA21113) has launched its first call for Inclusive Target Countries Conference Grants (CGs). The aim of these grants is to encourage the participation of young members from Inclusiveness Target Countries (ITCs) and Near Neighbour Countries (NNCs) in the activities related to GenE-Humdi COST Action purpose and to improve the quality of scientific research and training in these regions. PhD students, young researchers, and innovators under the age of 40 who are affiliated with an institution located in an ITC country are eligible to apply for the grant.
Individuals attending an in-person conference could receive up to €2000. The Grant Awarding Committee of the Action will assess each application based on the conference’s context, sessions, scientific topics and relevance, and contribution to the Action’s strategic priorities and objectives. The ITC Conference Grants of this first call will be available within the first Grant Period of the Action, i.e., by 31 October 2023.
Applicants need to have an e-COST profile as all applications must be processed through the e-COST online management tool. The deadline for the first round of applications is May 28th for applicants willing to assist to events starting after June 15th, and a second round´s deadline is June 25th for events starting after July 22th. The ITC CGs committee will review all applications, and the evaluation of applications will take about two weeks. The committee reserves the right to grant an amount that is less than the requested sum. The successful applicant will receive a Grant Letter that specifies the approved amount and the conditions that must be met to receive the grant.
GeneHumdi participates and promotes several Genome Editing related events, please refer to the grant bases, for suggested events. After the event, the grantee must submit required reports and relevant documentation in e-COST within 30 days after the end date of the activity or 15 days after the end of the Grant Period. The grantee must report the outcome of the presentation of the accepted contribution, the certificate of attendance, and the program of the conference or book of abstracts/proceedings indicating the presentation, following the indications in the grant announce bases.
For additional information on the submission process, applicants may refer to the reference document here For more information on GenE-Humdi, please visit the official webpage. If you have any questions or inquiries, please contact:
COST (European Cooperation in Science and Technology) is a funding organisation for research and innovation networks. Our Actions help connect research initiatives across Europe and beyond and enable researchers and innovators to grow their ideas in any science and technology field by sharing them with their peers. COST Actions are bottom-up networks with a duration of four years that boost research, innovation and careers.
